Physician profile
Martina H Wiedau
NPI 1528086824
$49,530.59
in general payments reported to CMS, 2019-2025
24 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $1,254 · 2021: $2,162 · 2022: $9,435 · 2023: $6,694 · 2024: $9,604 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,120 · Honoraria: $1,350 · Travel and Lodging: $1,328 · Food and Beverage: $1,171 · Education: $31.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,447.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,120.00 |
| Honoraria | $1,350.00 |
| Travel and Lodging | $1,328.34 |
| Food and Beverage | $1,170.94 |
| Education | $31.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $43,900.94 | 2019-2024 | |
| Amylyx Pharmaceuticals, INC. | $1,405.31 | 2023 | Relyvrio |
| Teva Pharmaceuticals USA, INC. | $1,139.04 | 2019-2021 | |
| Abbvie INC. | $1,106.91 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $776.26 | 2019-2023 | |
| Allergan, INC. | $170.27 | 2020-2021 | |
| Amgen INC. | $167.53 | 2020-2021 | |
| Emd Serono, INC. | $139.28 | 2019-2021 | |
| Lilly USA, LLC | $122.46 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $88.05 | 2021 | |
| Biogen, INC. | $67.70 | 2021-2022 | |
| Ucb, INC. | $59.23 | 2023-2025 | Zilbrysq |
| Csl Behring | $56.80 | 2022-2023 | Hizentra |
| Edw Pharma, INC. | $50.61 | 2020-2021 | |
| Acorda Therapeutics, INC | $48.72 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $47.62 | 2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $43.83 | 2020-2021 | |
| Bausch Health US, LLC | $36.16 | 2019 | |
| Integra Lifesciences Corporation | $32.10 | 2020 | |
| Pfizer INC. | $28.77 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $28.43 | 2024 | Dysport |
| Assertio Therapeutics, INC. | $14.57 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martina Wiedau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.